CN1250220C - 类大麻碱中心受体拮抗剂在制造用于使停止烟草消费容易化的药物中的应用 - Google Patents

类大麻碱中心受体拮抗剂在制造用于使停止烟草消费容易化的药物中的应用 Download PDF

Info

Publication number
CN1250220C
CN1250220C CNB018047130A CN01804713A CN1250220C CN 1250220 C CN1250220 C CN 1250220C CN B018047130 A CNB018047130 A CN B018047130A CN 01804713 A CN01804713 A CN 01804713A CN 1250220 C CN1250220 C CN 1250220C
Authority
CN
China
Prior art keywords
nicotine
administration
tobacco consumption
active component
compd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018047130A
Other languages
English (en)
Chinese (zh)
Other versions
CN1406128A (zh
Inventor
J·C·布兰查尔德
F·梅纳德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA, Sanofi Aventis France filed Critical Sanofi Synthelabo SA
Publication of CN1406128A publication Critical patent/CN1406128A/zh
Application granted granted Critical
Publication of CN1250220C publication Critical patent/CN1250220C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB018047130A 2000-02-09 2001-02-07 类大麻碱中心受体拮抗剂在制造用于使停止烟草消费容易化的药物中的应用 Expired - Fee Related CN1250220C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR00/01682 2000-02-09
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (2)

Publication Number Publication Date
CN1406128A CN1406128A (zh) 2003-03-26
CN1250220C true CN1250220C (zh) 2006-04-12

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018047130A Expired - Fee Related CN1250220C (zh) 2000-02-09 2001-02-07 类大麻碱中心受体拮抗剂在制造用于使停止烟草消费容易化的药物中的应用

Country Status (32)

Country Link
US (2) US6930122B2 (enExample)
EP (1) EP1257275B1 (enExample)
JP (2) JP2003522145A (enExample)
CN (1) CN1250220C (enExample)
AR (1) AR028505A1 (enExample)
AT (1) ATE292467T1 (enExample)
AU (1) AU781827B2 (enExample)
BG (2) BG110386A (enExample)
BR (1) BR0108126A (enExample)
CA (1) CA2397262C (enExample)
CZ (1) CZ296685B6 (enExample)
DE (1) DE60109903T2 (enExample)
DK (1) DK1257275T3 (enExample)
EE (1) EE04836B1 (enExample)
ES (1) ES2240416T3 (enExample)
FR (1) FR2804604B1 (enExample)
HU (1) HU225328B1 (enExample)
IL (1) IL150710A0 (enExample)
IS (1) IS6450A (enExample)
MX (1) MXPA02007766A (enExample)
NO (1) NO324521B1 (enExample)
NZ (1) NZ519924A (enExample)
PL (1) PL201685B1 (enExample)
PT (1) PT1257275E (enExample)
RS (1) RS50404B (enExample)
RU (1) RU2257207C2 (enExample)
SI (1) SI1257275T1 (enExample)
SK (1) SK284952B6 (enExample)
TW (1) TWI243677B (enExample)
UA (1) UA72783C2 (enExample)
WO (1) WO2001058450A2 (enExample)
ZA (1) ZA200205317B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
CN1568432A (zh) 2001-08-13 2005-01-19 霍尼韦尔国际公司 使用沟槽为晶片承载的半导体器件提供电流控制
NZ535349A (en) 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
AU2003215024B2 (en) 2002-03-26 2008-02-21 Merck Sharp & Dohme Corp. Spirocyclic amides as cannabinoid receptor modulators
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
AU2003275242B2 (en) 2002-09-27 2010-03-04 Merck Sharp & Dohme Corp. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2004058145A2 (en) 2002-12-19 2004-07-15 Merck & Co., Inc. Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US7169942B2 (en) * 2003-05-20 2007-01-30 University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7390835B2 (en) * 2003-10-30 2008-06-24 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
CA2586011C (en) 2004-07-12 2011-07-19 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
US7700597B2 (en) 2004-12-03 2010-04-20 Schering Corporation Substituted piperazines as CB1 antagonists
WO2007084450A2 (en) * 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
CA2666587C (en) * 2006-10-20 2015-12-22 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
WO2009005646A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
NO20023765D0 (no) 2002-08-08
FR2804604A1 (fr) 2001-08-10
UA72783C2 (en) 2005-04-15
FR2804604B1 (fr) 2005-05-27
HU225328B1 (en) 2006-09-28
CZ296685B6 (cs) 2006-05-17
EE04836B1 (et) 2007-06-15
HUP0300237A3 (en) 2003-09-29
ATE292467T1 (de) 2005-04-15
MXPA02007766A (es) 2002-10-11
SK11292002A3 (sk) 2003-02-04
US6930122B2 (en) 2005-08-16
WO2001058450A3 (fr) 2002-04-25
HUP0300237A2 (hu) 2003-07-28
SK284952B6 (sk) 2006-03-02
CZ20022698A3 (cs) 2002-11-13
US20030087933A1 (en) 2003-05-08
PL201685B1 (pl) 2009-04-30
DE60109903T2 (de) 2006-02-09
BR0108126A (pt) 2003-01-28
US20050187253A1 (en) 2005-08-25
WO2001058450A2 (fr) 2001-08-16
BG65856B1 (bg) 2010-03-31
RU2002118309A (ru) 2004-02-20
DK1257275T3 (da) 2005-08-08
TWI243677B (en) 2005-11-21
RS50404B (sr) 2009-12-31
AR028505A1 (es) 2003-05-14
NO324521B1 (no) 2007-11-12
JP2010018622A (ja) 2010-01-28
AU781827B2 (en) 2005-06-16
BG110386A (en) 2009-09-30
ZA200205317B (en) 2003-09-04
EP1257275A2 (fr) 2002-11-20
PL358221A1 (en) 2004-08-09
IL150710A0 (en) 2003-02-12
NO20023765L (no) 2002-10-09
PT1257275E (pt) 2005-07-29
ES2240416T3 (es) 2005-10-16
EP1257275B1 (fr) 2005-04-06
CA2397262A1 (en) 2001-08-16
DE60109903D1 (de) 2005-05-12
SI1257275T1 (en) 2005-10-31
YU59002A (sh) 2005-07-19
HK1051140A1 (en) 2003-07-25
CN1406128A (zh) 2003-03-26
IS6450A (is) 2002-06-28
EE200200439A (et) 2003-12-15
RU2257207C2 (ru) 2005-07-27
JP2003522145A (ja) 2003-07-22
AU3562001A (en) 2001-08-20
NZ519924A (en) 2005-01-28
BG106946A (bg) 2003-05-30
CA2397262C (en) 2007-09-11

Similar Documents

Publication Publication Date Title
CN1406128A (zh) 类大麻碱中心受体拮抗剂在制造用于使停止烟草消费容易化的药物中的应用
CN1227002C (zh) 包含聚醋酸乙烯酯和聚乙烯基吡咯烷酮的含活性成分漂浮形式及其用途与制备
US20240409514A1 (en) Methods for inhibiting native and promiscuous uptake of monoamine neurotransmitters
JP2021006534A (ja) 新規製剤
JPH10510559A (ja) シサプリドの即時放出性ｐＨ非依存性固形製剤
HUE035542T2 (hu) Brexpiprazolt vagy annak sóját és egy második hatóanyagot tartalmazó kombinációk központi idegrendszeri rendellenességek kezelésében történõ alkalmazásra
JPH08208471A (ja) 薬物反応の増強作用
WO2007074856A1 (ja) 口腔内崩壊性固形製剤の製造法
TW200914066A (en) Solid preparation
EP2124901A1 (en) Tablet preparation without causing a tableting trouble
US20120202869A1 (en) Antidepressant Oral Pharmaceutical Compositions
CN1271276A (zh) 经舌下或含服给药的控释药物
CN1886119A (zh) 泮托拉唑多颗粒制剂
US20120196917A1 (en) Antidepressant Oral Liquid Compositions
JP2007518755A (ja) モノアミン神経伝達物質再取り込み阻害剤及びｎ−メチル−ｄ−アスパラギン酸（ｎｍｄａ）受容体アンタゴニストを含む医薬組成物
CN1703203A (zh) 感官可接受的口腔内崩解组合物
TW201106991A (en) Tablets
CN1303280A (zh) 氟西汀及其对映体的稳定剂型
JP2002541098A (ja) ジプラシドン代謝産物を用いる神経弛緩薬性障害および関連障害を治療するための方法および組成物
JP2002538102A (ja) 光学的に純粋なｒ（＋）オンダンセトロンを使用する無呼吸および無呼吸障害の治療方法
CN1642532A (zh) 曲马多缓释制剂
CN101500567B (zh) P38激酶抑制剂治疗精神障碍的用途
CN104519874B (zh) 固体制剂
CN1250208C (zh) 氟西汀肠溶片
WO2001093844A2 (en) Compositions comprising a serotonin transporter inhibitor and a 5-ht1d antagonist

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060412

Termination date: 20100207